Bruised Sy­ros scores $130M PIPE from mar­quee group — while grab­bing $60M cash from all-stock merg­er

Amid a bear mar­ket that’s dent­ing biotech share prices every­where, rais­ing cash some­times takes a bit of cre­ative think­ing. Just ask Sy­ros Phar­ma­ceu­ti­cals.

The Cam­bridge …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER